- Home
- SRPT vs VRDN Comparison
SRPT vs VRDN Comparison
Compare SRPT & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRPT | VRDN |
|---|---|---|
| Founded | 1980 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SRPT | VRDN |
|---|---|---|
| Price | $15.58 | $19.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 29 | 14 |
| Target Price | $25.85 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 3.0M | 1.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $2,198,237,000.00 | $5,706,000.00 |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | N/A | $279.00 |
| P/E Ratio | $5.35 | ★ N/A |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $14.68 | $13.18 |
| 52 Week High | $25.32 | $34.29 |
Technical Indicators
Market Signals| Indicator | SRPT | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 34.07 | 56.78 |
| Support Level | N/A | $17.54 |
| Resistance Level | $18.16 | $20.00 |
| Average True Range (ATR) | 0.88 | 0.76 |
| MACD | -0.30 | -0.03 |
| Stochastic Oscillator | 4.46 | 69.17 |
Price Performance
Historical ComparisonAbout SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.